InotivNOTVQ -9.91% PS Ratio is 0.00 as of Jun. 24, 2026. The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Inotiv ranks worse than 497511.94% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Inotiv's share price is $0.01.
Inotiv's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $14.74. Hence, Inotiv's PS Ratio for today is 0.00.
The historical rank and industry rank for Inotiv's PS Ratio or its related term are showing as below:
During the past 13 years, Inotiv's highest PS Ratio was 8.76. The lowest was 0.01. And the median was 0.56.
NOTVQ's PS Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.79 * Ranked among companies with meaningful PS Ratio only.
Inotiv's Revenue per Sharefor the
three
months ended in Mar. 2026 was $3.40.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $14.74.
Warning Sign:
Inotiv Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Inotiv was -14.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -11.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 27.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 28.80% per year.
During the past 13 years, Inotiv's highest 3-Year average Revenue per Share Growth Rate was 74.90% per year. The lowest was -23.40% per year. And the median was 6.85% per year.
Back to Basics: PS Ratio
Inotiv (OTCPK:NOTVQ) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Inotiv PS Ratio Related Terms
Inotiv PS Ratio Historical Data
* Premium members only.
The historical data trend for Inotiv's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Inotiv's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's PS Ratio distribution charts can be found below:
* The bar in red indicates where Inotiv's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Inotiv's Share Price of today is $0.01. Inotiv's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Inotiv (NOTVQ) has a PS Ratio of 0.00 as of Jun. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Inotiv and its competitors. Over the past decade, Inotiv's PS Ratio has ranged from 0.01 to 8.76. According to the industry distribution chart, Inotiv ranks #999999 out of 201 companies in the Medical Diagnostics & Research industry.
Is Inotiv's PS Ratio too high?
Inotiv's current PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 8.76. Based on the distribution chart, Inotiv ranks #999999 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Inotiv's PS Ratio compare to NDRA and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #999999 out of 201 companies for PS Ratio. This places Inotiv in the lower half of its industry. The industry median PS Ratio is 2.79. Historically, Inotiv's own PS Ratio has ranged from 0.01 to 8.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.79, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Inotiv and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inotiv's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current PS Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Inotiv (NOTVQ), the current PS Ratio is 0.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NOTVQ has been successfully added to your 